These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11680988)

  • 21. Irritable bowel syndrome. New treatment drug on the market.
    Harv Health Lett; 2000 Jun; 25(8):7. PubMed ID: 10810051
    [No Abstract]   [Full Text] [Related]  

  • 22. [New therapeutic approaches in irritable bowel syndrome].
    Müller-Lissner SA
    Z Gastroenterol; 2000 Sep; 38(9):815-6. PubMed ID: 11072681
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.
    Horwitz BJ
    Health News; 2002 Oct; 8(10):1-2. PubMed ID: 12416480
    [No Abstract]   [Full Text] [Related]  

  • 24. Alosetron approved for treatment of irritable bowel syndrome.
    Miller JL
    Am J Health Syst Pharm; 2000 Mar; 57(6):519. PubMed ID: 10754758
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.
    Mayer EA; Berman S; Derbyshire SW; Suyenobu B; Chang L; Fitzgerald L; Mandelkern M; Hamm L; Vogt B; Naliboff BD
    Aliment Pharmacol Ther; 2002 Jul; 16(7):1357-66. PubMed ID: 12144587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].
    Delvaux M; Frexinos J
    Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C42-53. PubMed ID: 11787379
    [No Abstract]   [Full Text] [Related]  

  • 27. Alosetron in irritable bowel syndrome.
    McColl KE
    Lancet; 2000 Jul; 356(9224):164-5. PubMed ID: 10963271
    [No Abstract]   [Full Text] [Related]  

  • 28. Alosetron (Lotronex) for treatment of irritable bowel syndrome.
    Med Lett Drugs Ther; 2000 Jun; 42(1081):53-4. PubMed ID: 10872030
    [No Abstract]   [Full Text] [Related]  

  • 29. Alosetron for irritable bowel syndrome.
    Lièvre M
    BMJ; 2002 Sep; 325(7364):555-6. PubMed ID: 12228116
    [No Abstract]   [Full Text] [Related]  

  • 30. Review article: the safety and efficacy of alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients.
    Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():77-82. PubMed ID: 10429745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: clinical pharmacology of alosetron.
    Gunput MD
    Aliment Pharmacol Ther; 1999 May; 13 Suppl 2():70-6. PubMed ID: 10429744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.
    Palmer JB
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12511473
    [No Abstract]   [Full Text] [Related]  

  • 33. Peripherally acting therapies for the treatment of irritable bowel syndrome.
    Saad RJ
    Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?
    Shen B; Soffer EE
    Cleve Clin J Med; 2003 Jan; 70(1):64-5. PubMed ID: 12549728
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.
    Delvaux M; Louvel D; Mamet JP; Campos-Oriola R; Frexinos J
    Aliment Pharmacol Ther; 1998 Sep; 12(9):849-55. PubMed ID: 9768527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotoninergic neuroenteric modulators.
    Talley NJ
    Lancet; 2001 Dec; 358(9298):2061-8. PubMed ID: 11755632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response.
    Scherl E; Frissora CL
    Pharmacogenomics J; 2003; 3(2):64-6. PubMed ID: 12746730
    [No Abstract]   [Full Text] [Related]  

  • 40. Hypersensitivity and hyperreactivity in the irritable bowel syndrome: An opportunity for drug discovery.
    Sanger GJ
    Dig Dis; 1999; 17(2):90-9. PubMed ID: 10545714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.